News

A pending patent application covering amorphous rifaximin, an issued patent covering the product along with related intellectual property rights that was acquired by Olon from Apotex Pharmachem were

Conducted on 447 patients with previously untreated CLL and evaluated by an independent review committee (IRC), the study met its primary endpoint of progression free survival (PFS). Patients

With the acquisition of 500,000ft² commercial manufacturing facility, UPM expects to expand capacity for production of solid oral dosage tablets and capsules, in addition to semi-solid creams and

Under the terms of the strategic deal, complete ownership of Okairos will be transferred to GSK, including early stage assets for diseases such as respiratory syncytial virus, hepatitis

The partnership deals with integrating complementary capabilities and synergies of both the companies and plans for the long term supply of PAN resin and Zexlon film to Mitsui

Estonian Cancer Research Technology Development Center manager Riin Ehin was quoted by The Baltic Times citing Public Broadcasting as saying that production of the drug for rare types

Tafinlar is not indicated for the treatment of patients with wild-type BRAF melanoma, whereas Mekinist is not indicated for the treatment of patients who have received a prior

The agreement will help in the development of life science and protein assays by EMD Millipore for Luminex’s flexible platform. Under the terms of the agreement, EMD Millipore

Commenting on the agreement, ThromboGenics CEO Dr Patrik De Haes said, "This is an important step forward as we continue to build our ophthalmology franchise following the recent